The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


New Positive Data Seem to Support Drug Label Expansion

Research Report
  ()
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.

Results of Dermatitis Clinical Trial Due This Summer

Research Report
  ()
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.

New Drug for Heart Failure on Path to Approval, Analyst Says

Research Report
  ()
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Research Report
  ()
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.

Biotech Co. Advances 3 New Clinical Stage Assets

Research Report
  ()
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Research Report
  ()
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Research Report
  ()
The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Research Report
  ()
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success

Contributed Opinion
  ()
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough.

Approved Drug Shows Promise in Follicular Lymphoma

Research Report
  ()
Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report.

FDA Approval of Drug Could Be on the Way

Research Report
  ()
"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection.

Important Data for COVID Drug Candidate Due This Month

Research Report
  ()
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report.

Cancer Patients Have Partial Response With Drug

Research Report
  ()
The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report.

Cancer Targeting Drug Better Tolerated Than Others

Research Report
  ()
A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report.

50% Revenue Growth Expected This Year for Biopharma Co.

Research Report
  ()
The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report.

Target Price on Drug Co. Suggests Possible Huge Returns

Research Report
  ()
Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report.

Showing Results: 1 to 25 of 110 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts